nach oben

Erschienen in:

15.12.2017 | Original Article

Polymorphisms in inflammation-related genes and the risk of primary varicose veins in ethnic Russians

verfasst von: Alexandra Shadrina, Elena Voronina, Mariya Smetanina, Yakov Tsepilov, Kseniya Sevost’ianova, Andrey Shevela, Evgenii Seliverstov, Elena Zakharova, Evgeny Ilyukhin, Alexander Kirienko, Igor Zolotukhin, Maxim Filipenko

Erschienen in: Immunologic Research | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Inflammation was shown to be activated in varicose veins, although its role in the development of vein wall transformation remains inconclusive. We aimed to investigate the influence of 13 inflammation-related single nucleotide polymorphisms (SNPs) TNF rs1800629 and rs3093661, IL1A rs1800587, IL1RN rs4251961, IL6 rs1800795 and rs1800796, IFNG rs2430561, IL10 rs1800896, TGFB1 rs1800469, HIF1A rs11549465, NFKB1 rs28362491, and rs4648068 on the risk of primary varicose veins (PVVs) in ethnic Russians. We genotyped 709 patients with PVVs and 278 individuals without a history of chronic venous disease and performed a single SNP and a haplotype analysis. Several associations with P < 0.05 were revealed in our study. Variant allele HIF1A rs11549465 T, TNF rs3093661 A, and NFKB1 rs28362491 ATTG deletion showed the reverse association with PVV risk, and allele IL6 rs1800795 C was associated with the increased risk of the studied pathology. Haplotype analysis revealed associations of TNF haplotypes rs3093661 A-rs1800629 G and IL6 rs1800795 C-rs1800796 G with the decreased and the increased risk of PVVs, correspondingly. However, all the observed associations failed to reach statistical significance after the correction for multiple testing, which was set at a level of 10⁻³ due to many tests performed. Our study therefore provides evidence that investigated polymorphisms do not play a major role in susceptibility to PVVs.

Nur mit Berechtigung zugänglich

Segiet OA, Brzozowa M, Piecuch A, Dudek D, Reichman-Warmusz E, Wojnicz R. Biomolecular mechanisms in varicose veins development. Ann Vasc Surg. 2015;29(2):377–84. https://doi.org/10.1016/j.avsg.2014.10.009.CrossRefPubMed

Badier-Commander C, Couvelard A, Henin D, Verbeuren T, Michel J-B, Jacob M-P. Smooth muscle cell modulation and cytokine overproduction in varicose veins. An in situ study. J Pathol. 2001;193(3):398–407. https://doi.org/10.1002/path.819.CrossRefPubMed

Barallobre-Barreiro J, Oklu R, Lynch M, Fava M, Baig F, Yin X, et al. Extracellular matrix remodelling in response to venous hypertension: proteomics of human varicose veins. Cardiovasc Res. 2016;110(3):419–30. https://doi.org/10.1093/cvr/cvw075.CrossRefPubMedPubMedCentral

Lim CS, Davies AH. Pathogenesis of primary varicose veins. Br J Surg. 2009;96(11):1231–42. https://doi.org/10.1002/bjs.6798.CrossRefPubMed

Oklu R, Habito R, Mayr M, Deipolyi AR, Albadawi H, Hesketh R, et al. Pathogenesis of varicose veins. J Vasc Interv Radiol. 2012;23(1):33–9. https://doi.org/10.1016/j.jvir.2011.09.010.CrossRefPubMed

Krysa J, Jones GT, van Rij AM. Evidence for a genetic role in varicose veins and chronic venous insufficiency. Phlebology. 2012;27(7):329–35. https://doi.org/10.1258/phleb.2011.011030.CrossRefPubMed

Pfisterer L, König G, Hecker M, Korff T. Pathogenesis of varicose veins—lessons from biomechanics. Vasa. 2014;43(2):88–99. https://doi.org/10.1024/0301-1526/a000335.CrossRefPubMed

Lim CS, Gohel MS, Shepherd AC, Paleolog E, Davies AH. Venous hypoxia: a poorly studied etiological factor of varicose veins. J Vasc Res. 2011;48(3):185–94. https://doi.org/10.1159/000320624.CrossRefPubMed

Guzik B, Chwała M, Matusik P, Ludew D, Skiba D, Wilk G, et al. Mechanisms of increased vascular superoxide production in human varicose veins. Pol Arch Med Wewn. 2011;121(9):279–86.PubMed

10.

Anwar MA, Shalhoub J, Lim CS, Gohel MS, Davies AH. The effect of pressure-induced mechanical stretch on vascular wall differential gene expression. J Vasc Res. 2012;49(6):463–78. https://doi.org/10.1159/000339151.CrossRefPubMed

11.

Krzyściak W, Kowalska J, Kózka M, Papież MA, Kwiatek WM. Iron content (PIXE) in competent and incompetent veins is related to the vein wall morphology and tissue antioxidant enzymes. Bioelectrochemistry. 2012;87:114–23. https://doi.org/10.1016/j.bioelechem.2011.12.011.CrossRefPubMed

12.

Palazon A, Goldrath AW, Nizet V, Johnson RS. HIF transcription factors, inflammation, and immunity. Immunity. 2014;41(4):518–28. https://doi.org/10.1016/j.immuni.2014.09.008.CrossRefPubMedPubMedCentral

13.

Urbich C, Mallat Z, Tedgui A, Clauss M, Zeiher AM, Dimmeler S. Upregulation of TRAF-3 by shear stress blocks CD40-mediated endothelial activation. J Clin Invest. 2001;108(10):1451–8. https://doi.org/10.1172/JCI13620.

14.

del Rio SL, Aceves M, Dueñas AI, González-Fajardo JA, Vaquero C, Crespo MS, et al. Varicose veins show enhanced chemokine expression. Eur J Vasc Endovasc Surg. 2009;38(5):635–41. https://doi.org/10.1016/j.ejvs.2009.07.021.CrossRef

15.

Yasim A, Kilinc M, Aral M, Oksuz H, Kabalci M, Eroglu E, et al. Serum concentration of procoagulant, endothelial and oxidative stress markers in early primary varicose veins. Phlebology. 2008;23(1):15–20. https://doi.org/10.1258/phleb.2007.007014.CrossRefPubMed

16.

Poredos P, Spirkoska A, Rucigaj T, Fareed J, Jezovnik MK. Do blood constituents in varicose veins differ from the systemic blood constituents? Eur J Vasc Endovasc Surg. 2015;50(2):250–6. https://doi.org/10.1016/j.ejvs.2015.04.031.CrossRefPubMed

17.

Lattimer CR, Kalodiki E, Geroulakos G, Hoppensteadt D, Fareed J. Are inflammatory biomarkers increased in varicose vein blood? Clin Appl Thromb. 2016;22(7):656–64. https://doi.org/10.1177/1076029616645330.CrossRef

18.

Shadrina AS, Smetanina MA, Sevost’ianova KS, Seliverstov EI, Ilyukhin EA, Voronina EN, et al. Functional polymorphism rs1024611 in the MCP1 gene is associated with the risk of varicose veins of lower extremities. J Vasc Surg Venous Lymphat Disord. 2017;5(4):561–6. https://doi.org/10.1016/j.jvsv.2016.12.008.CrossRefPubMed

19.

Sokolova EA, Shadrina AS, Sevost’ianova KS, Shevela AI, Soldatsky EY, Seliverstov EI, et al. HFE p.C282Y gene variant is associated with varicose veins in Russian population. Clin Exp Med. 2016;16(3):463–70. https://doi.org/10.1007/s10238-015-0377-y.CrossRefPubMed

20.

Tanimoto K, Yoshiga K, Eguchi H, Kaneyasu M, Ukon K, Kumazaki T, et al. Hypoxia-inducible factor-1 polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis. 2003;24(11):1779–83. https://doi.org/10.1093/carcin/bgg132.CrossRefPubMed

21.

Fu XS, Choi E, Bubley GJ, Balk SP. Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. Prostate. 2005;63(3):215–21. https://doi.org/10.1002/pros.20190.CrossRefPubMed

22.

Karban AS, Okazaki T, Panhuysen CIM, Gallegos T, Potter JJ, Bailey-Wilson JE, et al. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet. 2004;13(1):35–45. https://doi.org/10.1093/hmg/ddh008.CrossRefPubMed

23.

Gautam A, Gupta S, Mehndiratta M, Sharma M, Singh K, Kalra OP, et al. Association of NFKB1 gene polymorphism (rs28362491) with levels of inflammatory biomarkers and susceptibility to diabetic nephropathy in Asian Indians. World J Diabetes. 2017;8(2):66–73. https://doi.org/10.4239/wjd.v8.i2.66.CrossRefPubMedPubMedCentral

24.

Chen Y, Lu R, Zheng H, Xiao R, Feng J, Wang H, et al. The NFKB1 polymorphism (rs4648068) is associated with the cell proliferation and motility in gastric cancer. BMC Gastroenterol. 2015;15(1):21. https://doi.org/10.1186/s12876-015-0243-0.CrossRefPubMedPubMedCentral

25.

Valente FP, Tan CR, Temple SE, Phipps M, Witt CS, Kaur G, et al. The evolution and diversity of TNF block haplotypes in European, Asian and Australian Aboriginal populations. Genes Immun. 2009;10(7):607–15. https://doi.org/10.1038/gene.2009.45.CrossRefPubMed

26.

Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci. U S A. 1997;94(7):3195–9. https://doi.org/10.1073/pnas.94.7.3195.CrossRef

27.

Kroeger KM, Carville KS, Abraham LJ. The −308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol. 1997;34(5):391–9. https://doi.org/10.1016/S0161-5890(97)00052-7.CrossRefPubMed

28.

Louis E, Franchimont D, Piron A, Gevaert Y, Schaaf-Lafontaine N, Roland S, et al. Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol. 1998;113(3):401–6. https://doi.org/10.1046/j.1365-2249.1998.00662.x.CrossRefPubMedPubMedCentral

29.

Dominici R, Cattaneo M, Malferrari G, Archi D, Mariani C, Grimaldi L, et al. Cloning and functional analysis of the allelic polymorphism in the transcription regulatory region of interleukin-1 alpha. Immunogenetics. 2002;54(2):82–6. https://doi.org/10.1007/s00251-002-0445-9.CrossRefPubMed

30.

Reiner AP, Wurfel MM, Lange LA, Carlson CS, Nord AS, Carty CL, et al. Polymorphisms of the IL1-receptor antagonist gene (IL1RN) are associated with multiple markers of systemic inflammation. Arterioscler Thromb Vasc Biol. 2008;28(7):1407–12. https://doi.org/10.1161/ATVBAHA.108.167437.CrossRefPubMedPubMedCentral

31.

Rafiq S, Stevens K, Hurst AJ, Murray A, Henley W, Weedon MN, et al. Common genetic variation in the gene encoding interleukin-1-receptor antagonist (IL-1RA) is associated with altered circulating IL-1RA levels. Genes Immun. 2007;8(4):344–51. https://doi.org/10.1038/sj.gene.6364393.CrossRefPubMed

32.

Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998;102(7):1369–76. https://doi.org/10.1172/JCI2629.CrossRefPubMedPubMedCentral

33.

Myśliwska J, Zorena K, Myśliwiec M, Malinowska E, Raczyńska K, Balcerska A. The -174GG interleukin-6 genotype is protective from retinopathy and nephropathy in juvenile onset type 1 diabetes mellitus. Pediatr Res. 2009;66(3):341–5. https://doi.org/10.1203/PDR.0b013e3181b1bd05.CrossRefPubMed

34.

Cole SW, Arevalo JM, Takahashi R, Sloan EK, Lutgendorf SK, Sood AK, et al. Computational identification of gene-social environment interaction at the human IL6 locus. Proc Natl Acad Sci U S A. 2010;107(12):5681–6. https://doi.org/10.1073/pnas.0911515107.CrossRefPubMedPubMedCentral

35.

Fang M, Huang Y, Zhang Y, Ning Z, Zhu L, Li X. Interleukin-6 -572C/G polymorphism is associated with serum interleukin-6 levels and risk of idiopathic pulmonary arterial hypertension. J Am Soc Hypertens. 2017;11(3):171–7. https://doi.org/10.1016/j.jash.2017.01.011.CrossRefPubMed

36.

Wong LYF, Leung RYH, Ong KL, Cheung BMY. Plasma levels of fibrinogen and C-reactive protein are related to interleukin-6 gene −572C>G polymorphism in subjects with and without hypertension. J Hum Hypertens. 2007;21(11):875–82. https://doi.org/10.1038/sj.jhh.1002233.CrossRefPubMed

37.

Pravica V, Perrey C, Stevens A, Lee JH, Hutchinson IV. A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. Hum Immunol. 2000;61(9):863–6. https://doi.org/10.1016/S0198-8859(00)00167-1.CrossRefPubMed

38.

Chen H, Wilkins LM, Aziz N, Cannings C, Wyllie DH, Bingle C, et al. Single nucleotide polymorphisms in the human interleukin-1B gene affect transcription according to haplotype context. Hum Mol Genet. 2006;15(4):519–29. https://doi.org/10.1093/hmg/ddi469.CrossRefPubMed

39.

Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997;24(1):1–8. https://doi.org/10.1111/j.1365-2370.1997.tb00001.x.CrossRefPubMed

40.

Hulkkonen J, Pertovaara M, Antonen J, Lahdenpohja N, Pasternack A, Hurme M. Genetic association between interleukin-10 promoter region polymorphisms and primary Sjögren’s syndrome. Arthritis Rheum. 2001;44(1):176–9. https://doi.org/10.1002/1529-0131(200101)44:1<176::AID-ANR23>3.0.CO;2-K.CrossRefPubMed

41.

Guo W, Dong Z, Guo Y, Chen Z, Yang Z, Kuang G, et al. Polymorphisms of transforming growth factor-β1 associated with increased risk of gastric cardia adenocarcinoma in north China. Int J Immunogenet. 2011;38(3):215–24. https://doi.org/10.1111/j.1744-313X.2010.00991.x.CrossRefPubMed

42.

Cao H, Zhou Q, Lan R, Røe OD, Chen X, Chen Y, et al. A functional polymorphism C-509T in TGFβ-1 promoter contributes to susceptibility and prognosis of lone atrial fibrillation in Chinese population. PLoS One. 2014;9(11):e112912. https://doi.org/10.1371/journal.pone.0112912.CrossRefPubMedPubMedCentral

43.

Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC, et al. Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet. 1999;8(1):93–7. https://doi.org/10.1093/hmg/8.1.93.CrossRefPubMed

44.

Eklöf B, Rutherford RB, Bergan JJ, Carpentier PH, Gloviczki P, Kistner RL, et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg. 2004;40(6):1248–52. https://doi.org/10.1016/j.jvs.2004.09.027.CrossRefPubMed

45.

Zolotukhin I, Seliverstov E, Shevtsov Y, Avakiants I, Nikishkov A, Tatarintsev A, et al. Prevalence and risk factors for chronic venous disease in Russian general population. Eur J Vasc Endovasc Surg. 2017;54(6):752–8. https://doi.org/10.1016/j.ejvs.2017.08.033.

46.

Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol. 2009;1(6):a001651. https://doi.org/10.1101/cshperspect.a001651.CrossRefPubMedPubMedCentral

47.

Gu L-Q, Zhu W, Pan C-M, Zhao L, Zhang M-J, Liu J-M, et al. Tumor necrosis factor alpha (TNF-alpha) polymorphisms in Chinese patients with Graves’ disease. Clin Biochem. 2010;43(3):223–7. https://doi.org/10.1016/j.clinbiochem.2009.08.012.CrossRefPubMed

48.

Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813(5):878–88. https://doi.org/10.1016/j.bbamcr.2011.01.034.CrossRefPubMed

49.

Lim CS, Kiriakidis S, Sandison A, Paleolog EM, Davies AH. Hypoxia-inducible factor pathway and diseases of the vascular wall. J Vasc Surg. 2013;58(1):219–30. https://doi.org/10.1016/j.jvs.2013.02.240.CrossRefPubMed

50.

Ghaderian SM, Lindsey NJ, Graham AM, Homer-Vanniasinkam S, Najar RA. Pathogenic mechanisms in varicose vein disease: the role of hypoxia and inflammation. Pathology. 2010;42(5):446–53. https://doi.org/10.3109/00313025.2010.493865.CrossRefPubMed

Titel: Polymorphisms in inflammation-related genes and the risk of primary varicose veins in ethnic Russians
verfasst von: Alexandra Shadrina
Elena Voronina
Mariya Smetanina
Yakov Tsepilov
Kseniya Sevost’ianova
Andrey Shevela
Evgenii Seliverstov
Elena Zakharova
Evgeny Ilyukhin
Alexander Kirienko
Igor Zolotukhin
Maxim Filipenko
Publikationsdatum: 15.12.2017
Verlag: Springer US
Erschienen in: Immunologic Research / Ausgabe 1/2018
Print ISSN: 0257-277X
Elektronische ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-017-8981-4

Neu im Fachgebiet HNO

16.04.2024 | HNO-Chirurgie | Nachrichten

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Polymorphisms in inflammation-related genes and the risk of primary varicose veins in ethnic Russians

Abstract

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update HNO

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Immunotherapy with interferon-α-induced dendritic cells for chronic HCV infection (the results of pilot clinical trial)

Screening HCV genotype-specific epitope peptides based on conserved sequence analysis and B cell epitope prediction in HCV E2 region

History of the antibody workshops

Th2-biased immune response and agglutinating antibodies generation by a chimeric protein comprising OmpC epitope (323–336) of Aeromonas hydrophila and LTB

Using circulating tumor cells to evaluate the efficacy of irreversible electroporation for unresectasble pancreatic cancer

Dual neutralization of TNFR-2 and MMP-2 regulates the severity of S. aureus induced septic arthritis correlating alteration in the level of interferon gamma and interleukin-10 in terms of TNFR2 blocking

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update HNO